Form 4: Outlook Therapeutics CFO Receives Stock Grant
Insider Transaction (Form 4)
Lawrence A Kenyon, Chief Financial Officer and a Director of Outlook Therapeutics, Inc., received 210,078 shares of common stock on July 21, 2026.
Summary
- Grant/award: acquired 210,078 Stock Option (Right to Buy) on July 21, 2026; holds 210,078 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lawrence A Kenyon — Director, Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-21 | Grant/award | Stock Option (Right to Buy) | 210,078 | — | — | 210,078 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-21 | Grant/award (210,078 shares) |
Keywords
insider transaction, Form 4, OTLK, Outlook Therapeutics, Inc., neutral, Lawrence A Kenyon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.